Novel scaffolds for modulation of TRPV1 identified with pharmacophore modeling and virtual screening

Future Medicinal Chemistry

Volumn 7, Issue 3, 2015, Pages 243-256

  Goldmann, Daria ^a   Pakfeifer, Peter ^a   Hering, Steffen ^a   Ecker, Gerhard F ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR SCAFFOLD; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; ANALGESIC AGENT; LIGAND; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG SCREENING; MODEL; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; VOLTAGE CLAMP TECHNIQUE; XENOPUS; ALGORITHM; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; DRUG EFFECTS; HUMAN; METABOLISM; PERIPHERAL NERVOUS SYSTEM;

ALGORITHMS; ANALGESICS, NON-NARCOTIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MODELS, MOLECULAR; PERIPHERAL NERVOUS SYSTEM; TRPV CATION CHANNELS;

EID: 84926321690     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.168     Document Type: Article

References (62)

1. Jara-Oseguera A, Nieto-Posadas A, Szallasi A, Islas LD, Rosenbaum T. Molecular mechanisms of TRPV1 channel activation. Open Pain J. 3, 68-81 (2010).
2. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389(6653), 816-824 (1997).
3. Jancso N, Jancso-Gabor A, Szolcsanyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br. J. Pharmacol. Chemother. 31(1), 138-151 (1967).
4. Premkumar LS. Targeting TRPV1 as an alternative approach to narcotic analgesics to treat chronic pain conditions. AAPS J. 12(3), 361-370 (2010).
5. Westaway SM. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J. Med. Chem. 50(11), 2589-2596 (2007).
6. Moran MM, Mcalexander MA, Biro T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat. Rev. Drug Discov. 10(8), 601-620 (2011).
7. Walpole CS, Bevan S, Bovermann G et al. The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J. Med. Chem. 37(13), 1942-1954 (1994).
8. Kim MS, Ryu H, Kang DW et al. 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region. J. Med. Chem. 55(19), 8392-8408 (2012).
9. Lee J, Kang SU, Kil MJ et al. Analysis of structure-activity relationships for the 'A-region' of N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as TRPV1 antagonists. Bioorg. Med. Chem. Lett. 15(18), 4136-4142 (2005).
10. Lee J, Jin MK, Kang SU et al. Analysis of structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists. Bioorg. Med. Chem. Lett. 15(18), 4143-4150 (2005).
11. Appendino G, Daddario N, Minassi A, Moriello AS, De Petrocellis L, Di Marzo V. The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. J. Med. Chem. 48(14), 4663-4669 (2005).
12. Blum CA, Caldwell T, Zheng X et al. Discovery of novel 6, 6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists. J. Med. Chem. 53(8), 3330-3348 (2010).
13. Doherty EM, Fotsch C, Bo Y et al. Discovery of potent, orally available vanilloid receptor-1 antagonists. Structureactivity relationship of N-aryl cinnamides. J. Med. Chem. 48(1), 71-90 (2005).
14. Shishido Y, Jinno M, Ikeda T et al. Synthesis of benzamide derivatives as TRPV1 antagonists. Bioorg. Med. Chem. Lett. 18(3), 1072-1078 (2008).
15. Jetter MC, Youngman MA, Mcnally JJ et al. N-isoquinolin-5-yl-N'-aralkyl-urea and-amide antagonists of human vanilloid receptor 1. Bioorg. Med. Chem. Lett. 14(12), 3053-3056 (2004).
16. Kym PR, Kort ME, Hutchins CW. Analgesic potential of TRPV1 antagonists. Bio Chem. Pharmacol. 78(3), 211-216 (2009).
17. Mcdonnell ME, Zhang SP, Nasser N, Dubin AE, Dax SL. 7-Hydroxynaphthalen-1-yl-urea and-amide antagonists of human vanilloid receptor 1. Bioorg. Med. Chem. Lett. 14(2), 531-534 (2004).
18. Zheng X, Hodgetts KJ, Brielmann H et al. From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist. Bioorg. Med. Chem. Lett. 16(19), 5217-5221 (2006).
19. Shao B, Huang J, Sun Q, Valenzano KJ, Schmid L, Nolan S. 4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists. Bioorg. Med. Chem. Lett. 15(3), 719-723 (2005).
20. Li FN, Kim NJ, Chang DJ et al. Synthesis and structural optimization of multiple H-bonding region of diarylalkyl (thio)amides as novel TRPV1 antagonists. Bioorg. Med. Chem. 17(24), 8149-8160 (2009).
21. Blum CA, Zheng X, Brielmann H et al. Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution. Bioorg. Med. Chem. Lett. 18(16), 4573-4577 (2008).
22. Lebsack AD, Branstetter BJ, Hack MD et al. Identification and synthesis of 2, 7-diamino-thiazolo[5, 4-d]pyrimidine derivatives as TRPV1 antagonists. Bioorg. Med. Chem. Lett. 19(1), 40-46 (2009).
23. Jetter MC, Youngman MA, Mcnally JJ et al. Heteroaryl betatetralin ureas as novel antagonists of human TRPV1. Bioorg. Med. Chem. Lett. 17(22), 6160-6163 (2007).
24. Tafesse L, Sun Q, Schmid L et al. Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists. Bioorg. Med. Chem. Lett. 14(22), 5513-5519 (2004).
25. Xi N, Bo Y, Doherty EM et al. Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists. Bioorg. Med. Chem. Lett. 15(23), 5211-5217 (2005).
26. Hodgetts KJ, Blum CA, Caldwell T et al. Pyrido[2, 3-b] pyrazines, discovery of TRPV1 antagonists with reduced potential for the formation of reactive metabolites. Bioorg. Med. Chem. Lett. 20(15), 4359-4363 (2010).
27. Li FN, Kim NJ, Paek SM et al. Design, synthesis, and biological evaluation of novel diarylalkyl amides as TRPV1 antagonists. Bioorg. Med. Chem. 17(10), 3557-3567 (2009).
28. Schmidt RG, Bayburt EK, Latshaw SP et al. Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists. Bioorg. Med. Chem. Lett. 21(5), 1338-1341 (2011).
29. Takahashi E, Hirano N, Nagahara T et al. Discovery of potent transient receptor potential vanilloid 1 antagonists: design and synthesis of phenoxyacetamide derivatives. Bioorg. Med. Chem. Lett. 23(11), 3154-3156 (2013).
30. Kim HS, Jin MK, Kang SU et al. alpha-Methylated simplified resiniferatoxin (sRTX) thiourea analogues as potent and stereospecific TRPV1 antagonists. Bioorg. Med. Chem. Lett. 24(12), 2685-2688 (2014).
31. Goldmann D, Montanari F, Richter L, Zdrazil B, Ecker GF. Exploiting open data: a new era in pharmacoinformatics. Future Med. Chem. 6(5), 503-514 (2014).
32. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model 45(1), 160-169 (2005).
33. Lee J, Kim SY, Lee J et al. Analysis of structure-activity relationships with the N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea template for vanilloid receptor 1 antagonism. Bioorg. Med. Chem. 12(13), 3411-3420 (2004).
34. Swanson DM, Dubin AE, Shah C et al. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl) piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl) amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem. 48(6), 1857-1872 (2005 ).
35. Cheung WS, Calvo RR, Tounge BA et al. Discovery of piperidine carboxamide TRPV1 antagonists. Bioorg. Med. Chem. Lett. 18(16), 4569-4572 (2008).
36. Rebolledo CL, Sotelo-Hitschfeld P, Brauchi S, Olavarria MZ. Design and synthesis of conformationally restricted capsaicin analogues based in the 1, 3, 4-thiadiazole heterocycle reveal a novel family of transient receptor potential vanilloid 1 (TRPV1) antagonists. Eur. J. Med. Chem. 66, 193-203 (2013).
37. Kim KH. 3-D-QSAR analysis of N-(3-acyloxy-2-benzylpropyl)-N'-dihydroxytetrahydrobenzazepine and tetrahydroisoquinoline and N-(3-acyloxy-2-benzylpropyl)-N'-(4-hydroxy-3-methoxybenzyl) thioureas analogues as potent vanilloid receptor ligands. Bioorg. Med. Chem. 10(5), 1367-1372 (2002).
38. Kristam R, Parmar V, Viswanadhan VN. 3D-QSAR analysis of TRPV1 inhibitors reveals a pharmacophore applicable to diverse scaffolds and clinical candidates. J. Mol. Graph. Model. 45, 157-172 (2013).
39. Ryu H, Jin MK, Kim SY et al. Stereospecific high-affinity TRPV1 antagonists: chiral N-(2-benzyl-3-pivaloyloxypropyl) 2-[4-(methylsulfonylamino)phenyl]propionamide analogues. J. Med. Chem. 51(1), 57-67 (2008).
40. Kim YS, Kil MJ, Kang SU et al. N-4-t-Butylbenzyl 2-(4-methylsulfonylaminophenyl) propanamide TRPV1 antagonists: structure-activity relationships in the A-region. Bioorg. Med. Chem. 20(1), 215-224 (2012).
41. Bhondwe RS, Kang DW, Kim MS et al. Structure-activity relationships and molecular modeling of the N-(3-pivaloyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino) benzyl] thiourea template for TRPV1 antagonism. Bioorg. Med. Chem. Lett. 22(11), 3656-3660 (2012).
42. Kim NJ, Li FN, Lee JH et al. Heterocycle-linked phenylbenzyl amides as novel TRPV1 antagonists and their TRPV1 binding modes: constraint-induced enhancement of in vitro and in vivo activities. Chem. Asian J. 8(2), 400-409 (2013).
43. Garami A, Shimansky YP, Pakai E, Oliveira DL, Gavva NR, Romanovsky AA. Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J. Neurosci. 30(4), 1435-1440 (2010).
44. Gaulton A, Bellis LJ, Bento AP et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, d1100-d1107 (2012).
45. Tsareva DA, Ecker GF. How far could we go with open data-a case study for TRPV1 antagonists. Mol. Inform. 32(5-6), 555-562 (2013).
46. Hawkins PC, Skillman AG, Warren GL, Ellingson BA, Stahl MT. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J. Chem. Inf. Model. 50(4), 572-584 (2010).
47. Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55(14), 6582-6594 (2012).
48. Durant JL, Leland BA, Henry DR, Nourse JG. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Model. 42(6), 1273-1280 (2002).
49. Methfessel C, Witzemann V, Takahashi T, Mishina M, Numa S, Sakmann B. Patch clamp measurements on Xenopus laevis oocytes: currents through endogenous channels and implanted acetylcholine receptor and sodium channels. Pflugers Arch. 407(6), 577-588 (1986).
50. Wolber G, Dornhofer AA, Langer T. Efficient overlay of small organic molecules using 3D pharmacophores. J. Comput. Aided Mol. Des. 20(12), 773-788 (2006).
51. Brown BS, Keddy R, Perner RJ et al. Discovery of TRPV1 antagonist ABT-116. Bioorg. Med. Chem. Lett. 20(11), 3291-3294 (2010).
52. Lebsack AD, Rech JC, Branstetter BJ et al. 1, 2-diaminoethane-substituted-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-d] azepines as TRPV1 antagonists with improved properties. Bioorg. Med. Chem. Lett. 20(23), 7142-7146 (2010).
53. Xiao D, Palani A, Aslanian R et al. Spiro-piperidine azetidinones as potent TRPV1 antagonists. Bioorg. Med. Chem. Lett. 19(3), 783-787 (2009).
54. Westaway SM, Thompson M, Rami HK et al. Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1. Bioorg. Med. Chem. Lett. 18(20), 5609-5613 (2008).
55. Mcdonnell ME, Zhang SP, Dubin AE, Dax SL. Synthesis and in vitro evaluation of a novel iodinated resiniferatoxin derivative that is an agonist at the human vanilloid VR1 receptor. Bioorg. Med. Chem. Lett. 12(8), 1189-1192 (2002).
56. Cao E, Liao M, Cheng Y, Julius D. TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 504(7478), 113-118 (2013).
57. Goldin AL. Expression of ion channels in Xenopus oocytes. In: Expression and Analysis of Recombinant Ion Channels: from Structural Studies to Pharmacological Screening. Clare JJ, Trezise DJ (Eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 1-25 (2006).
58. Holzer P. The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor. Br. J. Pharmacol. 155(8), 1145-1162 (2008).
59. Tafesse L, Kanemasa T, Kurose N et al. Structureactivity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-5-[(1S)-1, 2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyrid yl]-3, 6-dihydro-2H-pyridine 1-carboxamide (V116517) as a clinical candidate for pain management. J. Med. Chem. 57(15), 6781-6794 (2014).
60. Voight EA, Gomtsyan AR, Daanen JF et al. Discovery of (R)-1-(7-chloro-2, 2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)ur ea (A-1165442): a temperatureneutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy. J. Med. Chem. 57(17), 7412-7424 (2014).
61. Life Chemicals www.lifechemicals.com
62. DUD-E decoy generator. http://dude.docking.org/generate